| Literature DB >> 31136039 |
Erwin Krikken1, Wybe J M van der Kemp1, Vitaliy Khlebnikov1, Thijs van Dalen2, Maartje Los3, Hanneke W M van Laarhoven4, Peter R Luijten1, Maurice A A J van den Bosch5, Dennis W J Klomp1, Jannie P Wijnen1.
Abstract
PURPOSE: Metabolic MRI is a noninvasive technique that can give new insights into understanding cancer metabolism and finding biomarkers to evaluate or monitor treatment plans. Using this technique, a previous study has shown an increase in pH during neoadjuvant chemotherapy (NAC) treatment, while recent observation in a different study showed a reduced amide proton transfer (APT) signal during NAC treatment (negative relation). These findings are counterintuitive, given the known intrinsic positive relation of APT signal to pH.Entities:
Keywords: 31P-MRSI; 7 T MRI; APT CEST; breast cancer
Mesh:
Substances:
Year: 2019 PMID: 31136039 PMCID: PMC6772111 DOI: 10.1002/nbm.4110
Source DB: PubMed Journal: NMR Biomed ISSN: 0952-3480 Impact factor: 4.044
Demographics, tumor characteristics and pathological response of breast cancer patients undergoing neoadjuvant chemotherapy
| Patient | Age (years) | Treatment regime | ER | PR | HER2/neu | TNM |
|---|---|---|---|---|---|---|
| 1 | 58 | 4 x AC – 4 x docetaxel | + | − | + | T2N1M0 |
| 2 | 55 | 3 x FEC – 3 x docetaxel | + | + | − | T2N0M0 |
| 3 | 58 | 3 x FEC – 3 x docetaxel | + | + | − | T2N1M0 |
| 4 | 38 | 3 x FEC – 3 x docetaxel | + | − | − | T3N2M0 |
| 5 | 42 | 4 x AC – 4 x docetaxel | − | − | − | T2N0M0 |
| 6 | 38 | 4 x AC – 12 x paclitaxel | − | − | − | T2N3M0 |
| 7 | 36 | 4 x AC – 4 x docetaxel | + | + | − | T2N1M0 |
| 8 | 47 | 4 x AC – 4 x docetaxel | − | − | + | T2N0M0 |
| 9 | 42 | 4 x AC – 4 x docetaxel | − | − | + | T2N0M0 |
| 10 | 43 | 4 x AC – 4 x docetaxel | − | − | − | T2N0M0 |
| 11 | 40 | 4 x AC – 12 x paclitaxel | + | + | + | T1N0M0 |
| 12 | 41 | 4 x AC – 12 x paclitaxel | − | − | + | T2N1M0 |
| 13 | 55 | 4 x AC – 12 x paclitaxel | − | − | − | T2N0M0 |
| 14 | 53 | 4 x AC – 12 x paclitaxel | + | − | − | T2N1M0 |
| 15 | 45 | 4 x AC – 12 x paclitaxel | − | − | − | T2N1M0 |
| 16 | 48 | 4 x AC – 12 x paclitaxel | − | − | + | T2N0M0 |
| 17 | 53 | 6 x docetaxel ‐ AC | − | − | − | T2N0M0 |
| 18 | 61 | 6 x docetaxel ‐ AC | + | + | − | T2N1M0 |
| 19 | 34 | 6 x docetaxel ‐ AC | − | − | − | T2N0M0 |
| 20 | 54 | 6 x docetaxel ‐ AC | + | + | − | T2N1M0 |
| 21 | 33 | 6 x docetaxel ‐ AC | − | − | − | T2N1M0 |
| 22 | 51 | 6 x docetaxel ‐ AC | + | + | − | T2N0M0 |
AC, adriamycin and cyclophosphamide; ER, estrogen receptor; FEC, 5‐fluorouracil, epirubicin and cyclophosphamide; HER2/neu, human epidermal growth factor receptor 2; PR, progesterone receptor; TNM stage, classification of malignant tumors (tumor, nodes, metastasis).
Starting points and boundaries of all‐fit parameters of the three‐pool Lorentzian fit. The chemical shift δ and FWHM Γ are given in ppm
| Start | Lower | Upper | |
|---|---|---|---|
| Zbase | 0.5 | 0.5 | 1 |
| Awater | 0.8 | 0 | 1 |
| Γwater | 1 | 0.1 | 2.5 |
| δwater | 0 | ‐1 | 1 |
| AMT | 0.1 | 0 | 1 |
| ΓMT | 5 | 3 | 100 |
| δMT | 0 | −0.5 | 0.5 |
| Aamide | 0.1 | 0 | 1 |
| Γamide | 1 | 1 | 1.5 |
| δamide | 3.5 | 3.3 | 3.7 |
δ, chemical shift; Γ, FWHM; MT, magnetization transfer.
Figure 1Example of acquired and calculated data (patients 13, upper half, and 14, lower half from Table 1 before the start of NAC treatment). (A,D) coronal slices of the calculated APT maps with the ROIs of the tumor (orange) overlaid on top of a fat suppressed T1‐weighted 3D FFE (TR = 7.1 ms; TE = 3.2 ms; flip angle = 8°; resolution of 0.7 mm3; SENSE 4 x 2 [RL x FH], 1–4–6‐4‐1 spectral spatial RF pulse for fat suppression). Note that both 31P‐MRS and CEST analysis were performed on the entire tumor volume; only one coronal slice is shown here. (B,E) corresponding 31P‐MRSI spectra originating from the ROI where nine metabolites are visible. (C,F) three‐pool Lorentzian fit of the Z‐spectra of water (yellow line), magnetization transfer effect (MT; green line), amide proton transfer (APT; purple line) and the full fit consisting of the three fits (orange)
Figure 2Relation between APT signal and pH measured by CEST and 31P‐MRS (based on the chemical shift between pi and α‐ATP) for all patients before and after the first cycle of NAC treatment. The hypothesis (dashed gray line) was calculated based on Sun and Sorensen6 using , with = 26.8, = 3.4×106, and = 11.2 and normalized to the measured data. The linear regression is shown by the solid black line which is already statistically significant without correcting for known (Sun and Sorensen) pH effects (P < 0.05). Note that the measured data is contradicting the hypothesis; a decreasing APT‐CEST with increasing pH opposed to the hypothesis; *, Statistically significant
Figure 3Relation of APT signal with pH (left) before and (right) after the first cycle of NAC treatment. Separating the data in these two groups resulted in a linear regression which was no longer statistically significant for both. The outliers are shown in gray
Figure 4Relation of PME/PDE and PE/pi with pH (left) before and (right) after the first cycle of NAC treatment. The linear regressions are shown as black solid lines. The linear regression between PE/pi and pH before the start of NAC treatment was statistically significant. The outliers are shown in gray. *, Statistically significant